Further, the highest rate of amplification was in TNBC (3.2–6.7%), ER− (2.8–5.4%) and ER−/HER2+ tumors (1.3–6.5%), whereas EGFR amplification was relatively less common in ER+ breast cancers (0.8–1.4%). This evidence concerns the gene EGFR and breast carcinoma.